Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

138 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).
Church LD, Savic S, McDermott MF. Church LD, et al. Among authors: mcdermott mf. Biologics. 2008 Dec;2(4):733-42. doi: 10.2147/btt.s3167. Biologics. 2008. PMID: 19707454 Free PMC article.
Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism.
Church LD, McDermott MF. Church LD, et al. Among authors: mcdermott mf. Nat Clin Pract Rheumatol. 2009 Jan;5(1):14-5. doi: 10.1038/ncprheum0959. Epub 2008 Nov 18. Nat Clin Pract Rheumatol. 2009. PMID: 19015646 No abstract available.
Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD, McDermott MF. Church LD, et al. Among authors: mcdermott mf. Expert Rev Clin Immunol. 2010 Nov;6(6):831-41. doi: 10.1586/eci.10.66. Expert Rev Clin Immunol. 2010. PMID: 20979548
Inflammation: canakinumab for the cryopyrin-associated periodic syndromes.
Savic S, McDermott MF. Savic S, et al. Among authors: mcdermott mf. Nat Rev Rheumatol. 2009 Oct;5(10):529-30. doi: 10.1038/nrrheum.2009.195. Nat Rev Rheumatol. 2009. PMID: 19798026 No abstract available.
The RA-MAP Consortium: a working model for academia-industry collaboration.
Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulz-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium. Cope AP, et al. Among authors: mcdermott mf. Nat Rev Rheumatol. 2018 Jan;14(1):53-60. doi: 10.1038/nrrheum.2017.200. Epub 2017 Dec 7. Nat Rev Rheumatol. 2018. PMID: 29213124 Free PMC article. Review.
Clinical genetics in 2014: New monogenic diseases span the immunological disease continuum.
Savic S, McDermott MF. Savic S, et al. Among authors: mcdermott mf. Nat Rev Rheumatol. 2015 Feb;11(2):67-8. doi: 10.1038/nrrheum.2014.215. Epub 2014 Dec 23. Nat Rev Rheumatol. 2015. PMID: 25536483
Inflammasome inhibition under physiological and pharmacological conditions.
Caseley EA, Poulter JA, Rodrigues F; Immunome Project Consortium for Autoinflammatory Disorders(ImmunAID), McDermott MF. Caseley EA, et al. Among authors: mcdermott mf. Genes Immun. 2020 Aug;21(4):211-223. doi: 10.1038/s41435-020-0104-x. Epub 2020 Jul 17. Genes Immun. 2020. PMID: 32681062 Free article. Review.
COVID-19 meets Cystic Fibrosis: for better or worse?
Peckham D, McDermott MF, Savic S, Mehta A. Peckham D, et al. Among authors: mcdermott mf. Genes Immun. 2020 Aug;21(4):260-262. doi: 10.1038/s41435-020-0103-y. Epub 2020 Jul 1. Genes Immun. 2020. PMID: 32606316 Free article. Review.
Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations.
Lara-Reyna S, Holbrook J, Jarosz-Griffiths HH, Peckham D, McDermott MF. Lara-Reyna S, et al. Among authors: mcdermott mf. Cell Mol Life Sci. 2020 May 4. doi: 10.1007/s00018-020-03540-9. Online ahead of print. Cell Mol Life Sci. 2020. PMID: 32367193 Free article. Review.
Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis.
Jarosz-Griffiths HH, Scambler T, Wong CH, Lara-Reyna S, Holbrook J, Martinon F, Savic S, Whitaker P, Etherington C, Spoletini G, Clifton I, Mehta A, McDermott MF, Peckham D. Jarosz-Griffiths HH, et al. Among authors: mcdermott mf. Elife. 2020 Mar 2;9:e54556. doi: 10.7554/eLife.54556. Elife. 2020. PMID: 32118580 Free PMC article.
138 results
Jump to page
Feedback